Neos, Teva settle litigation over ADHD drug

The settlement includes a licensing deal that will allow Teva to market a generic version of Cotempla beginning mid-2026.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.